Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heartcel
- Development stage
- Phase 2
- Lead developer
- Celixir
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
Heartcel is an allogeneic immunomodulatory progenitor (iMP) cell therapy developed by Cell Therapy Ltd. (CTL) for the treatment of severe heart failure and ischemic cardiomyopathy. The therapy consists of specialized mesenchymal precursor cells that are delivered via intramyocardial injection, typically during coronary artery bypass graft (CABG) surgery. Heartcel's mechanism of action involves the immunomodulation of the cardiac environment to promote the regeneration of heart muscle and the reversal of myocardial fibrosis (scarring). Clinical data from Phase 2 trials have demonstrated improvements in cardiac function and a reduction in scar tissue. The developer has established strategic partnerships with Daiichi Sankyo for the Japanese market and Zhongyuan Union for development in China, leveraging accelerated regulatory pathways for regenerative medicines.
- Brand names
- Heartcel
- Other names
- allogeneic immunomodulatory progenitor cellsimmunomodulatory progenitor cells
02
Targets
MARCO
Beyond the preview
Go deeper on Heartcel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heartcel.